Tag: mental health

Love & Other Drugs: The Couples Using Psychedelics as a Way To Get Closer

Some couples like to take time off and wander the world to recharge, rejuvenate and reconnect with each other. Others prefer a different kind of trip. 

Psychedelics are increasingly gaining prominence as well as regulatory approval as a form of treatment for mental health disorders ranging from PTSD to anxiety. This has also sparked a larger conversation on whether using hallucinogens like psilocybin mushrooms or LSD could then also emerge as a form of relationship therapy, given that these substances have the ability to curb inhibitions and change the way we perceive reality. 

The rise and rise of psychedelic wellness has also led to couples experimenting with the substances together, either to forge stronger bonds, deal with deep-seated issues in a controlled setting or simply share the euphoric experience together. In fact, though psychedelics are not legal in most countries, relationship counsellors are increasingly advocating their use in counselling sessions, where a couple is administered a mild dosage in a controlled environment, asked leading questions about their hopes and fantasies while they’re tripping, and given calculated counselling based on their experiences. 

“Psilocybin has incredible [potential] as a catalyst for such therapy because it tears down all your walls and filters, and changes the way you think about the relationship,” Kripi Malviya, a psychologist and founder of de-addiction and rehabilitation centre TATVA, told VICE. 

Keep reading

The Emerging Magic Mushroom Monopoly

In December 2017, one of the godfathers of the contemporary psychedelic renaissance, Bob Jesse, penned a manifesto for the commercial era of hallucinogens, one that echoed as far and wide as when Timothy Leary famously evangelized, “Turn on, tune in, drop out,” in 1966. Jesse delivered a very different kind of message: “Open science for all!”

A philanthropist and independent researcher, Jesse was instrumental to reviving a new wave of medical interest into psychedelic-assisted therapy starting in the 1990s. This new form of therapy offers a revolutionary approach to treating the rising cases of depression and anxiety in the U.S. But Jesse began to see this pioneering research pillaged by Big Pharma, as soon as it showed commercial value as a breakthrough treatment for mental illness.

In the manifesto, Jesse took a stand against would-be monopolists for flagrantly misusing patent laws, advocating instead for a shared creative commons for psychedelic research, with limited intellectual-property rights. The statement attracted over 100 co-signers, including every major figure in the psychedelic research and NGO community, from philanthropic funders to grassroots advocates.

But there was a notable absence from the list: the founders of Compass Pathways, a rapidly growing psychedelic therapy company bankrolled by major investors, notably Peter Thiel, the PayPal co-founder and right-wing political financier.

“It was very suspicious when they didn’t sign on to the letter. It gave a lot of people pause about what their plans were,” said Carey Turnbull, a longtime philanthropist in the psychedelic community who has become one of Compass Pathways’ main detractors.

Compass’s founders—millionaire couple George Goldsmith and Ekaterina Malievskaia—had already raised eyebrows by quietly transitioning from a charity organization to a for-profit corporation in 2017. Compass was also conducting dubious drug trials on the Isle of Man, an infamous tax haven for the uber-wealthy with lax regulatory oversight. Suspicions abounded about the unusually restrictive contracts it pushed researchers to sign, and reports that Compass had blocked other organizations from signing a deal with one of their drug manufacturers.

The unwillingness to sign the letter was more than a snub. It was a harbinger of things to come.

Keep reading

Hallucinogen in ‘magic mushrooms’ relieves depression in largest clinical trial to date

Psilocybin, the hallucinogen found in “magic mushrooms,” helped to relieve symptoms in people with hard-to-treat depression in the largest clinical trial of its kind to date, the trial’s organizers announced Tuesday (Nov. 9).

Earlier this year, a small study suggested that psilocybin might work as well as the common antidepressant escitalopram (Lexapro) at relieving moderate to severe depression, and other past research has hinted at the drug’s promise, Live Science previously reported. But this new trial, conducted by the pharmaceutical company Compass Pathways, is the largest gold-standard trial of psilocybin to date, so its results could carry more weight than previous research, STAT reported. 

Keep reading

Lockdown has caused a mental-health crisis

What’s strange is that a mental-health lobby that has spent years redefining mental illness to include more and more people, and spent years discussing the potential social causes of this supposed ‘crisis’, is strangely hesitant to criticise lockdown. This is despite the fact that lockdown forces us into circumstances pretty much guaranteed to increase anxiety, depression and debilitating mental illnesses

A major survey by Mind, the mental-health charity, has found that two thirds of adults and three quarters of young people with existing mental-health problems have experienced worsening mental health over the course of the pandemic. In addition, more than one in five adults with no previous experience of such problems described their mental health as poor or very poor. One in four of those who tried to access support was unable to get it from the NHS.

Keep reading

Ease restrictions on medical psychedelics to aid research, experts say

Potential treatments for severe depression, addiction and other mental health disorders are being held up by excessive restrictions on psilocybin, the active ingredient in magic mushrooms, scientists and politicians have said.

Clinical trials suggest that psilocybin may be a safe and effective medicine for patients with certain psychiatric illnesses who do not respond to talking therapies, antidepressants and other drugs. But researchers say their work is being stymied by the government placing the strictest possible controls on the chemical compound.

In a report published on Monday, the Adam Smith Institute, a free market thinktank, and the Conservative drug policy reform group, urge ministers to order a review of psilocybin and remove the obstacles faced by researchers.

Under Home Office regulations, psilocybin is classified as a schedule 1 drug, along with raw opium, LSD, ecstasy and cannabis, and is not considered a medicinal compound. While clinical trials are allowed under licence, obtaining one takes more time and money than many researchers can afford, the authors say.

Robin Carhart-Harris Read more

The report calls on government to make psilocybin a schedule 2 drug, a move that would dramatically cut the cost and time taken to obtain a licence and remove the stigma surrounding research into the drug.

Keep reading